{"title":"Production and radiochemical separation of Tb-161 as a feasible beta therapeutic radioisotope from reactor irradiated Gd target","authors":"","doi":"10.1016/j.chroma.2024.465439","DOIUrl":null,"url":null,"abstract":"<div><div>Terbium-161 (<sup>161</sup>Tb) is a promising therapeutic radionuclide that has gained significant attention in the field of nuclear medicine in recent years. <sup>161</sup>Tb has several favorable characteristics that make it a valuable candidate for targeted radionuclide therapy. The production of No-carrier-added <sup>161</sup>Tb was carried out by the neutron activation of natural gadolinium target in the Egyptian Second Research Reactor (ETRR-2) at a thermal neutron flux position of 1.8 × 10<sup>14</sup> ncm<sup>-2</sup>s<sup>-1</sup>. The radioactivities of <sup>161</sup>Tb as well as coproduced Gd radioimpurities were computed theoretically by the MCNPX2.7.0 code and verified by actual measurements, where accepted discrepancies were obtained. The purification of <sup>161</sup>Tb from irradiated Gd target was developed by Chelex-100 resin. The elution performance was studied using different eluents, and 0.1 M HNO<sub>3</sub> was found to be the best medium to obtain a high separation efficiency of more than 92% in a short time. The eluted <sup>161</sup>Tb was of high chemical, radiochemical, and radionuclidic purities, indicating its potential for effective application in radiopharmaceutical preparation.</div></div>","PeriodicalId":347,"journal":{"name":"Journal of Chromatography A","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chromatography A","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0021967324008136","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
Terbium-161 (161Tb) is a promising therapeutic radionuclide that has gained significant attention in the field of nuclear medicine in recent years. 161Tb has several favorable characteristics that make it a valuable candidate for targeted radionuclide therapy. The production of No-carrier-added 161Tb was carried out by the neutron activation of natural gadolinium target in the Egyptian Second Research Reactor (ETRR-2) at a thermal neutron flux position of 1.8 × 1014 ncm-2s-1. The radioactivities of 161Tb as well as coproduced Gd radioimpurities were computed theoretically by the MCNPX2.7.0 code and verified by actual measurements, where accepted discrepancies were obtained. The purification of 161Tb from irradiated Gd target was developed by Chelex-100 resin. The elution performance was studied using different eluents, and 0.1 M HNO3 was found to be the best medium to obtain a high separation efficiency of more than 92% in a short time. The eluted 161Tb was of high chemical, radiochemical, and radionuclidic purities, indicating its potential for effective application in radiopharmaceutical preparation.
期刊介绍:
The Journal of Chromatography A provides a forum for the publication of original research and critical reviews on all aspects of fundamental and applied separation science. The scope of the journal includes chromatography and related techniques, electromigration techniques (e.g. electrophoresis, electrochromatography), hyphenated and other multi-dimensional techniques, sample preparation, and detection methods such as mass spectrometry. Contributions consist mainly of research papers dealing with the theory of separation methods, instrumental developments and analytical and preparative applications of general interest.